Increased insulin‐stimulated endothelin‐1 release is a distinct vascular phenotype distinguishing Cushing's disease from metabolic syndrome
- 9 February 2007
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 66 (4) , 586-592
- https://doi.org/10.1111/j.1365-2265.2007.02774.x
Abstract
Objective Although much is known about the anti‐inflammatory effects of an acute corticosteroid therapy, little is known about the effects on chronic hypercortisolism on endothelial dysfunction and proinflammatory alterations in patients with Cushing's disease (CD). Patients and methods We studied 9 patients with CD, 10 patients with metabolic syndrome and 27 normal controls. The tests consisted of an intravenous bolus of 0·1 U/kg insulin combined with a euglycaemic clamp technique with an arterialized forearm and assessment of the training parameters deep‐venous balance of forearm glucose uptake (as an index of insulin sensitivity); NOx (nitric oxide end‐products), c‐GMP (second messenger of nitric oxide) and endothelin‐1 release, as indices of endothelial function and proinflammatory systemic markers. Results Forearm glucose uptake incremental area was significantly lower in Cushing's disease and in the metabolic syndrome than in controls, suggesting a state of severe insulin resistance. Compared to controls and to the metabolic syndrome, basal and insulin‐stimulated NOx release incremental areas were significantly reduced in Cushing's disease, while forearm c‐GMP release was similarly decreased in CD and metabolic syndrome. By contrast, endothelin‐1 incremental areas after insulin bolus were significantly higher in CD than in controls and the metabolic syndrome, in the presence of increased TNF‐alpha, IL‐6 and CRP levels. Forearm glucose uptake incremental area significantly correlated with NOx incremental area, forearm c‐GMP release incremental area, TNF‐alpha levels and ET‐1 incremental area. Conclusions In patients with CD, supraphysiological insulin levels are not able to overcome the insulin resistance due to chronic hypercortisolism. Furthermore, an increased proatherogenic risk profile is characterized by decreased nitric oxide synthesis and activity, enhanced endothelin‐1 levels and increased proinflammatory markers.Keywords
This publication has 36 references indexed in Scilit:
- The endothelin receptor antagonist decreases ischemia/reperfusion-induced tumor necrosis factor production in isolated rat heartsInternational Journal of Cardiology, 2005
- Insulin resistance, hyperleptinemia and endothelial dysfunction in coronary restenosisCurrent Opinion in Pharmacology, 2005
- TNF-α induces interleukin-8 and endothelin-1 expression in human endothelial cells with different redox pathwaysBiochemical and Biophysical Research Communications, 2005
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph pituitary adenomasExperimental and Clinical Endocrinology & Diabetes, 2000
- CORTISOL AND HYPERTENSIONClinical and Experimental Pharmacology and Physiology, 1998
- Effect of endothelin‐1 (1‐31) on extracellular signal‐regulated kinase and proliferation of human coronary artery smooth muscle cellsBritish Journal of Pharmacology, 1998
- Carbohydrate and Lipid Metabolism in Endogenous Hypercortisolism: Shared Features with Metabolic Syndrome X and NIDDM.Endocrine Journal, 1996
- Contribution of endogenous generation of endothelin-1 to basal vascular toneThe Lancet, 1994
- Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo.Journal of Clinical Investigation, 1993